19p13.1 Is a triple-negative-specific breast cancer susceptibility locus

KN Stevens; Z Fredericksen; CM Vachon; X Wang; S Margolin; A Lindblom; H Nevanlinna; D Greco; K Aittomak̈i; C Blomqvist; J Chang-Claude; A Vrieling; D Flesch-Janys; HP Sinn; S Wang-Gohrke; S Nickels; H Brauch; YD Ko; HP Fischer; RK Schmutzler; A Meindl; CR Bartram; S Schott; C Engel; AK Godwin; JE Weaver; HB Pathak; P Sharma; H Brenner; H Mul̈ler; V Arndt; C Stegmaier; P Miron; D Yannoukakos; A Stavropoulou; G Fountzilas; HJ Gogas; R Swann; M Dwek; A Perkins; RL Milne; J Benit́ez; MP Zamora; JIA Peŕez; SE Bojesen; SF Nielsen; BG Nordestgaard; H Flyger; P Gueńel; T Truong; F Menegaux; E Cordina-Duverger; B Burwinkel; F Marme; A Schneeweiss; C Sohn; E Sawyer; I Tomlinson; MJ Kerin; J Peto; N Johnson; O Fletcher; I Dos Santos Silva; PA Fasching; MW Beckmann; A Hartmann; AB Ekici; A Lophatananon; K Muir; P Puttawibul; S Wiangnon; MK Schmidt; A Broeks; LM Braaf; EH Rosenberg; JL Hopper; C Apicella; DJ Park; MC Southey; AJ Swerdlow; A Ashworth; O Nicholas; MJ Schoemaker; H Anton-Culver; A Ziogas; L Bernstein; CC Dur; CY Shen; JC Yu; HM Hsu; CN Hsiung; U Hamann; T Dun̈nebier; T Rud̈iger; HU Ulmer; PP Pharoah; AM Dunning; MK Humphreys; Q Wang; A Cox

Journal article

19p13.1 Is a triple-negative-specific breast cancer susceptibility locus

KN Stevens, Z Fredericksen, CM Vachon, X Wang, S Margolin, A Lindblom, H Nevanlinna, D Greco, K Aittomak̈i, C Blomqvist, J Chang-Claude, A Vrieling, D Flesch-Janys, HP Sinn, S Wang-Gohrke, S Nickels, H Brauch, YD Ko, HP Fischer, RK Schmutzler Show all

Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2012

DOI: 10.1158/0008-5472.CAN-11-3364

Abstract

The 19p13.1 breast cancer susceptibility locus is a modifier of breast cancer risk in BRCA1 mutation carriers and is also associated with the risk of ovarian cancer. Here, we investigated 19p13.1 variation and risk of breast cancer subtypes, defined by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status, using 48,869 breast cancer cases and 49,787 controls from the Breast Cancer Association Consortium (BCAC). Variants from 19p13.1 were not associated with breast cancer overall or with ER-positive breast cancer but were significantly associated with ER-negative breast cancer risk [rs8170 OR, 1.10; 95% confidence interval (CI), 1.05-1...

View full abstract

University of Melbourne Researchers

Roger Milne Author

Daniel Park Author

Melissa Southey Author

Graham Giles Author

Related Projects (2)

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

NIH AUSTRALIAN BREAST CANCER FAMILY REGISTRY SOUTHEY-HOPPER

DESCRIPTION (provided by applicant): The broad objective of the Breast Cancer Family Registry (Breast CFR) is to establish and maintain a hy..

Grants

Awarded by European Commission

Funding Acknowledgements

This work was supported by the NIH grant CA122340, a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), the Komen Foundation for the Cure and the Breast Cancer Research Foundation (BCRF); the BCAC is funded by Cancer Research UK (C1287/A10118 and C1287/A12014), by the European Community's Seventh Framework Programme under grant agreement no. 223175 (HEALTH-F2-2009-223175; COGS), and by the European Union COST programme (BM0606). D.F. Easton is a Principal Research Fellow of Cancer Research UK; SBCS: Breast Cancer Campaign (2004 Nov 49 to A. Cox) and Yorkshire Cancer Research Core Funding (Institute for Cancer Studies); ABCS: Dutch Cancer Society grant (NKI 2009-4363 and NKI 2007-3839 to M.K. Schmidt) and the Dutch National Genomics Initiative; ACP: Breast Cancer Research Trust, UK. E. Sawyer is funded by National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London. I. Tomlinson is funded by the Oxford Biomedical Research Centre; ABCFS, NC-BCFR and OFBCR: National Cancer Institute, NIH under RFA-CA-06-503, and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Northern California Cancer Center (U01 CA69417), University of Melbourne (U01 CA69638); ABCFS: National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia), and the Victorian Breast Cancer Research Consortium. J.L. Hopper is a National Health and Medical Research Council (NHMRC) Australia Fellow and a Victorian Breast Cancer Research Consortium Group Leader. M.C. Southey is an NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader; CNIO-BCS: Genome Spain Foundation, the Red Tematica de Investigacion Cooperativa en Cancer and grants from the Asociacion Espanola Contra el Cancer and the Fondo de Investigacion Sanitario (PI081583 and PI081120); The California Teachers Study: California Breast Cancer Act of 1993, NIH (R01 CA77398), the Lon V Smith Foundation [LVS39420]), and the California Breast Cancer Research Fund (contract 97-10500); UCIBCS: NIH (CA58860 and CA92044) and the Lon V Smith Foundation (LVS39420); ESTHER: Baden Wurttemberg Ministry of Science, Research and Arts, and the VERDI study supported by a grant from the German Cancer Aid (Deutsche Krebshilfe); GENICA: Federal Ministry of Education and Research (BMBF) Germany (01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114), the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ) Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, and the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany: KBCP: Finnish Cancer Society, the Academy of Finland (grant number 127220), the special Government Funding (EVO) of Kuopio University Hospital (grant number 5654113 and 5501) and by the strategic funding of the University of Eastern Finland; OBCS: Finnish Cancer Foundation, the Academy of Finland, the University of Oulu, the Oulu University Hospital and Biocenter Oulu; RPCI: P30 grant to RPCI (CA016056-32); The Breakthrough Generations Study: Breakthrough Breast Cancer and the Institute of Cancer Research (ICR). ICR acknowledges NHS funding to the NIHR Biomedical Research Centre; PBCS: Intramural Research Funds of the National Cancer Institute, Bethesda, MD; HEBCS: Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, and the Sigrid Juselius Foundation; MARIE: Deutsche Krebshilfe e.V., grant number 70-2892-BR I, the Hamburg Cancer Society, the German Cancer Research Center (DKFZ), and the Federal Ministry of Education and Research (BMBF) Germany grant 01KH0402; GESBC: Deutsche Krebshilfe e. V. (70492) and the state of Baden-Wurttemberg through the Medical Faculty of the University of Ulm (P.685); BSUCH: Dietmar Hopp Foundation, the German Cancer Research Center, DKFZ, and the Helmholtz association; GC-HBOC: Deutsche Krebshilfe (107054), the Center of Molecular Medicine, Cologne, the German Cancer Research Center, DKFZ, and the Helmholtz society; BBCS: Cancer Research UK, Breakthrough Breast Cancer and the National Cancer Research Network (NCRN); kConFab: National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, and Cancer Australia #628333; LMBC: 'Stichting tegen Kanker' (232-2008 and 196-2010); MCCS: Australian National Health and Medical Research Council (grants #209057, 251533, 396414, and 504711), Cancer Council Victoria, and VicHealth; ORIGO: Dutch Cancer Society; SEARCH: Cancer Research UK (C8197/A10123, C8197/A10123, and C490/A10124). A.M. Dunning was supported by Cancer Research UK grant (C8197/A10865) and by the Joseph Mitchell Fund; FCCC: NIH (U01 CA69631, 5U01 CA113916 to A.K. Godwin), the Eileen Stein Jacoby Fund, The University of Kansas Cancer Center, and the Kansas Bioscience Authority Eminent Scholar Program. A.K. Godwin is the Chancellors Distinguished Chair in Biomedical Sciences endowed Professor.